📊 XAIR Key Takeaways
Is Beyond Air, Inc. (XAIR) a Good Investment?
Beyond Air is a pre-commercial medical device company with only $5.8M in revenue but $23M in annual losses and $13.7M free cash burn, leaving approximately 6 months of runway with $6.6M in cash. A 2.7% gross margin and -379% operating margin indicate fundamental business model failures at current scale, while $22M in long-term debt cannot be serviced from deeply negative cash flows.
Why Buy Beyond Air, Inc. Stock? XAIR Key Strengths
- Medical device sector offers high-growth potential if product achieves regulatory approval and market adoption
- Strong current ratio (5.12x) and quick ratio (4.77x) provide adequate short-term liquidity coverage
- Net loss and diluted EPS improved year-over-year, indicating some operational trending positive from prior period
XAIR Stock Risks: Beyond Air, Inc. Investment Risks
- Critical liquidity crisis: 6-month cash runway at current $13.7M annual free cash burn rate without capital raise or revenue acceleration
- Catastrophically low gross margin (2.7%) and operating margin (-379%) indicate fundamental business model dysfunction or severe pricing/cost structure problems
- Unsustainable debt burden: $22M long-term debt with negative interest coverage (-7.5x) cannot be serviced from negative operating cash flows, requiring immediate refinancing or capital injection
Key Metrics to Watch
- Monthly cash burn rate and cash balance trajectory - critical for survival timeline and capital raise necessity
- Revenue growth and gross margin expansion - required to achieve path toward operating profitability
- Debt refinancing activities and equity capital raises - essential indicators of whether the company can extend its runway
Beyond Air, Inc. (XAIR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.12x current ratio provides a solid financial cushion.
XAIR Profit Margin, ROE & Profitability Analysis
XAIR vs Healthcare Sector: How Beyond Air, Inc. Compares
How Beyond Air, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Beyond Air, Inc. Stock Overvalued? XAIR Valuation Analysis 2026
Based on fundamental analysis, Beyond Air, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Beyond Air, Inc. Balance Sheet: XAIR Debt, Cash & Liquidity
XAIR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Beyond Air, Inc.'s revenue has declined by 52% over the 5-year period, indicating business contraction. The most recent EPS of $-1.82 indicates the company is currently unprofitable.
XAIR Revenue Growth, EPS Growth & YoY Performance
XAIR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $1.1M | -$7.3M | $-0.85 |
| Q2 2026 | $798.0K | -$7.9M | $-1.25 |
| Q1 2026 | $683.0K | -$7.7M | $-1.53 |
| Q3 2025 | $391.0K | -$13.0M | $-0.15 |
| Q3 2024 | $391.0K | -$12.7M | $-0.43 |
| Q2 2024 | $239.0K | -$12.0M | $-0.28 |
| Q1 2024 | $59.0K | -$10.9M | $-0.27 |
| Q3 2022 | $149.0K | -$5.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Beyond Air, Inc. Dividends, Buybacks & Capital Allocation
XAIR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Beyond Air, Inc. (CIK: 0001641631)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XAIR
What is the AI rating for XAIR?
Beyond Air, Inc. (XAIR) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XAIR's key strengths?
Claude: Medical device sector offers high-growth potential if product achieves regulatory approval and market adoption. Strong current ratio (5.12x) and quick ratio (4.77x) provide adequate short-term liquidity coverage.
What are the risks of investing in XAIR?
Claude: Critical liquidity crisis: 6-month cash runway at current $13.7M annual free cash burn rate without capital raise or revenue acceleration. Catastrophically low gross margin (2.7%) and operating margin (-379%) indicate fundamental business model dysfunction or severe pricing/cost structure problems.
What is XAIR's revenue and growth?
Beyond Air, Inc. reported revenue of $5.8M.
Does XAIR pay dividends?
Beyond Air, Inc. does not currently pay dividends.
Where can I find XAIR SEC filings?
Official SEC filings for Beyond Air, Inc. (CIK: 0001641631) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XAIR's EPS?
Beyond Air, Inc. has a diluted EPS of $-3.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XAIR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Beyond Air, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XAIR stock overvalued or undervalued?
Valuation metrics for XAIR: ROE of -283.2% (sector avg: 15%), net margin of -397.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XAIR stock in 2026?
Our dual AI analysis gives Beyond Air, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XAIR's free cash flow?
Beyond Air, Inc.'s operating cash flow is $-13.2M, with capital expenditures of $478.0K. FCF margin is -236.9%.
How does XAIR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -397.9% (avg: 12%), ROE -283.2% (avg: 15%), current ratio 5.12 (avg: 2).
Is Beyond Air, Inc. carrying too much debt?
XAIR has a debt-to-equity ratio of 2.71x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 5.12 suggests adequate short-term liquidity.